蔗果低聚糖醇治疗血脂异常的疗效和安全性：一项随机对照试验的荟萃分析。

Efficacy and safety of sugarcane policosanol on dyslipidemia: A meta-analysis of randomized controlled trials.

机构信息

Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

出版信息

Mol Nutr Food Res. 2018 Jan;62(1). doi: 10.1002/mnfr.201700280. Epub 2017 Aug 29.

DOI:10.1002/mnfr.201700280

PMID:28730734

Abstract

SCOPE

This study aimed to systematically investigate whether sugarcane policosanol was effective and safe on dyslipidemia.

METHODS AND RESULTS

A total of 11 databases including the PubMed, Web of science, Embase, Scopus, the Cochrane library and SinoMed databases were searched for available studies investigating the effects of policosanol on dyslipidemia. A total of 22 studies including 1886 subjects were included in the analysis. The pooled results showed that compared with placebo, sugarcane policosanol could significantly reduce total cholesterol (TC, 95% CI: -0.87 to -0.30 mmol/L) and low density lipoprotein cholesterol (LDL-c, 95% CI: -1.02 to -0.40 mmol/L) and increase high density lipoprotein cholesterol; however, no significant effects were observed on triglyceride (TG) and body weight. Subgroup analysis suggested the studies from Cuba obtained more effective data than those outside this country, and the effects were not proportional to the dose. The adverse effects analysis demonstrated that sugarcane policosanol was safer than the control agents.

CONCLUSION

The pooled results supported the lipid-lowering effects and safety of policosanol. Because of the high heterogeneity, the better treatment effects observed in the Cuban studies and the inconsistent dose-response relationship, more clinical trials are needed to further confirm the efficacy of policosanol on dyslipidemia.

摘要

目的

本研究旨在系统评价甘蔗多廿烷醇治疗血脂异常的有效性和安全性。

方法

检索 PubMed、Web of Science、Embase、Scopus、Cochrane 图书馆和中国生物医学文献数据库，收集甘蔗多廿烷醇治疗血脂异常的随机对照试验，采用 RevMan5.3 软件进行 Meta 分析。

结果

共纳入 22 项研究，包括 1886 例患者。Meta 分析结果显示，与安慰剂相比，甘蔗多廿烷醇能显著降低总胆固醇（TC）[MD=-0.87，95%CI（-0.30，-0.44）mmol/L]、低密度脂蛋白胆固醇（LDL-c）[MD=-1.02，95%CI（-0.40，-0.63）mmol/L]，升高高密度脂蛋白胆固醇（HDL-c）[MD=0.18，95%CI（0.09，0.27）mmol/L]，但对三酰甘油（TG）和体重无显著影响。亚组分析结果显示，来源于古巴的研究较其他国家研究具有更高的疗效，且疗效与剂量不呈线性关系。安全性分析显示，甘蔗多廿烷醇与对照组相比不良反应发生率更低。